Vanda Pharmaceuticals Inc. Quarterly Operating Income (Loss) in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Vanda Pharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2010 to Q3 2024.
  • Vanda Pharmaceuticals Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$11M, a 83.5% decline year-over-year.
  • Vanda Pharmaceuticals Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$37.5M, a 16265% decline year-over-year.
  • Vanda Pharmaceuticals Inc. annual Operating Income (Loss) for 2023 was -$14M, a 320% decline from 2022.
  • Vanda Pharmaceuticals Inc. annual Operating Income (Loss) for 2022 was $6.33M, a 85% decline from 2021.
  • Vanda Pharmaceuticals Inc. annual Operating Income (Loss) for 2021 was $42.2M, a 54.8% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$37.5M -$11M -$5.01M -83.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$32.5M -$10.1M -$7.28M -254% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$25.2M -$9.24M -$11.2M -561% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$14M -$7.09M -$13.7M -207% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-08
Q3 2023 -$229K -$6M -$9.9M -253% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $9.67M -$2.87M -$6.33M -183% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $16M $2M +$9.67M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $6.33M $6.63M -$2.01M -23.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-08
Q3 2022 $8.34M $3.91M -$6.91M -63.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $15.2M $3.46M -$8.91M -72% Apr 1, 2022 Jun 30, 2022 10-Q 2023-07-28
Q1 2022 $24.2M -$7.67M -$18M -174% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $42.2M $8.64M -$1.82M -17.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-08
Q3 2021 $44M $10.8M +$3.08M +39.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $40.9M $12.4M +$3.2M +34.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $37.7M $10.3M +$10.5M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $27.2M $10.5M +$6.21M +146% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-11
Q3 2020 $21M $7.74M -$3.02M -28% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $24M $9.17M -$724K -7.32% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $24.8M -$125K +$1.96M +94% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $22.8M $4.24M -$4.91M -53.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-11
Q3 2019 $27.7M $10.8M +$4.53M +72.6% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-11
Q2 2019 $23.2M $9.9M +$5.98M +153% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-11
Q1 2019 $17.2M -$2.09M -$4.53M -185% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-11
Q4 2018 $21.7M $9.15M +$11.3M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 $10.4M $6.23M +$11.2M Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 -$718K $3.91M +$5.84M Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 -$6.56M $2.44M +$10.3M Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 -$16.9M -$2.15M -$1.5M -229% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-19
Q3 2017 -$15.4M -$4.92M -$4.27M -654% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-19
Q2 2017 -$11.1M -$1.92M +$2.87M +59.8% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-19
Q1 2017 -$14M -$7.91M +$4.57M +36.6% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-19
Q4 2016 -$18.6M -$654K +$14.2M +95.6% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-15
Q3 2016 -$32.8M -$653K +$8.89M +93.2% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-15
Q2 2016 -$41.7M -$4.79M +$669K +12.3% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-15
Q1 2016 -$42.4M -$12.5M -$2.18M -21.2% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-15
Q4 2015 -$40.2M -$14.9M -$84.6M -121% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-17
Q3 2015 $44.4M -$9.54M -$8.09M -559% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-17
Q2 2015 $52.5M -$5.46M +$16.1M +74.7% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-17
Q1 2015 $36.3M -$10.3M +$16.3M +61.3% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-17
Q4 2014 $20.1M $69.7M +$77.5M Oct 1, 2014 Dec 31, 2014 10-K 2016-02-12
Q3 2014 -$57.4M -$1.45M +$3.98M +73.3% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-12
Q2 2014 -$61.4M -$21.6M -$18.2M -533% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-12
Q1 2014 -$43.2M -$26.6M -$22M -482% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-12
Q4 2013 -$21.2M -$7.79M -$1.36M -21.2% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-13
Q3 2013 -$19.8M -$5.43M -$36K -0.67% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-13
Q2 2013 -$19.8M -$3.41M +$4.67M +57.8% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-13
Q1 2013 -$24.5M -$4.57M +$3.75M +45.1% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-13
Q4 2012 -$28.2M -$6.43M -$520K -8.8% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-25
Q3 2012 -$27.7M -$5.4M -$2.1M -63.8% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-25
Q2 2012 -$25.6M -$8.09M -$6.57M -434% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-25
Q1 2012 -$19M -$8.32M -$15.3M -219% Jan 1, 2012 Mar 31, 2012 10-K 2014-02-25
Q4 2011 -$3.71M -$5.91M Oct 1, 2011 Dec 31, 2011 10-K 2013-02-26
Q3 2011 -$3.29M -$4.04M -543% Jul 1, 2011 Sep 30, 2011 10-K 2013-02-26
Q2 2011 -$1.51M -$2.67M -231% Apr 1, 2011 Jun 30, 2011 10-K 2013-02-26
Q1 2011 $7M Jan 1, 2011 Mar 31, 2011 10-K 2013-02-26
Q3 2010 $743K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-07
Q2 2010 $1.16M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.